Teva's Partner Alvotech Receives Complete Response Letter For AVT02 BLA

Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has issued a complete response letter to its partner Alvotech (ALVO) for the Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira (adalimumab).